

CURRICULUM VITAE

SCOTT DAVID RAMSEY, M.D., Ph.D.

Full Member
Cancer Prevention Program
Fred Hutchinson Cancer Research Center
1100 Fairview Avenue North, M2-B230
Seattle, Washington 98109-1024
sramsey@fhcrc.org

Educational Background

- B.S., University of Iowa, Iowa City, Iowa. Economics and General Science (double major), honors thesis in economics. Summa Cum Laude
- M.D., University of Iowa College of Medicine, Iowa City, Iowa
- Ph.D., Health Economics, Wharton School, University of Pennsylvania, Philadelphia, Pennsylvania

Professional Positions and Training

- Internship and Residency in Internal Medicine, Department of Internal Medicine, University of Washington, Seattle, WA
- Fellow in General Internal Medicine, VA Medical Center/University of Washington, Seattle, WA
- Chief Medical Resident, Department of Medicine, University of Washington Medical Center, Seattle, WA
- 1994–1995 Acting Instructor of Medicine, Department of Medicine, University of Washington, Seattle, WA
- 1995–1997 Acting Assistant Professor, Division of General Internal Medicine, University of Washington, Seattle, WA
- 1995–1997 Acting Assistant Professor, Department of Health Services, University of Washington, Seattle, WA
- 1995–1998 Staff Physician, VA Puget Sound Health Care System, Seattle Division, WA
- 1995–2000 Director of Clinical Economics, Center for Cost and Outcomes Research, Departments of Medicine and Health Services, University of Washington, Seattle, WA
- 1997–2000 Assistant Professor, Division of General Internal Medicine, University of Washington, Seattle, WA
- 1997–2000 Assistant Professor, Department of Health Services, University of Washington, Seattle, WA
- 1997–2000 Assistant Member (Joint), Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA
- 1995–present Investigator (Adjunct), Center for Health Studies, Group Health Cooperative, Seattle, WA
- 1998–present Staff physician, University of Washington Medical Center, Seattle, WA
- 1999–present Member, Institute for Public Health Genetics, School of Public Health, University of Washington, Seattle, WA
- 2000–2005 Associate Member, Cancer Prevention Program, Division of Public Health Science, Fred Hutchinson Cancer Research Center, Seattle, WA
- 2001–present Associate Professor, Division of General Internal Medicine, University of Washington, Seattle, WA
- 2001–present Associate Professor (Adjunct), Pharmaceutical Outcomes, Research, and Policy Program, Department of Pharmacy, University of Washington, Seattle, WA
- 2005–present Full Member, Cancer Prevention Program, Division of Public Health Science, Fred Hutchinson Cancer Research Center, Seattle, WA

Scholarships, Fellowships, Honors and Awards

- Phi Eta Sigma—freshman honor society, University of Iowa
- University of Iowa Merit Award
- Chester A. Phillips Scholarship, University of Iowa
- Mortar Board, University of Iowa
- Omicron Delta Kappa—national leadership society, University of Iowa
- Beta Gamma Sigma—honorary fraternity in business, University of Iowa
- University of Iowa Certificate of Achievement (highest University award granted to undergraduates)
- E. Lester Williams Scholarship, University of Iowa
- Kellogg Washington Health Policy Fellowship, Wharton School
- Dean's Scholarship, Wharton School
- University Research Foundation support grant, Wharton School
- University of Iowa, College of Medicine: John and Oral Sebelin Award, Outstanding Student in Internal Medicine
- 1994 Cecile Lehman Mayer Research Award recipient, American College of Chest Physicians, Presentation: The cost-effectiveness of lung transplantation
- 1995 Robert H. Williams Award, American Federation for Clinical Research regional meeting, Presentation: Estimated costs of alternative treatments for stress urinary incontinence
- 1996 Robert Wood Johnson Faculty Support Award
- 1997 Howard Temin Career Development Award, National Cancer Institute, Cost-Effectiveness of Genetic Screening for Hereditary Nonpolyposis Colon Cancer

Board Certification

- American Board of Internal Medicine
- Recertification, American Board of Internal Medicine

License

----present Washington state license #---

Professional Activities

Professional Memberships

American College of Physicians
International Health Economics Association
International Society for Pharmacoeconomic and Outcomes Research
American Society of Clinical Oncology
International Association for the Study of Lung Cancer
Society for Medical Decision Making
Cancer Intervention and Surveillance Network

Special National Government Responsibilities

Medical Devices Dispute Resolution Panel, Food and Drug Administration (Chairman), August 2000–present (1 of 3 voting members, 4-year term, reappointed to second term 2004)

Study Sections

SNEM-4 Study Section, National Institutes of Health (ad hoc member)

Consensus Panels

Chair, Special Task Force on standards for designing, conducting, and reporting cost-effectiveness analyses alongside clinical trials, International Society for Pharmacoeconomic and Outcomes Research, 2004-present

Advisory Boards

National Cancer Policy Board, Institute of Medicine of the National Academies, 2005- present

Ethical Legal and Social Implications (ELSI) Research Advisory Group, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 2002-present

Family History Working Group, Centers for Disease Control and Prevention, Atlanta, GA, 2002-present

Managed Care Advisory Board, Genentech, Inc., 2001–2003

Special National Responsibilities

Board of Directors, International Society for Pharmacoeconomic and Outcomes Research

Member, Pharmacy and Therapeutics Committee, Caremark, Inc. (2nd largest Pharmaceutical Benefits Management firm in the United States), Chicago, IL

Member, Pharmacy and Therapeutics Committee, Regence Blue Shield, Portland, OR

Member, Pharmacy and Therapeutics Committee, Prescription Solutions (PacifiCare), San Diego, CA

Editorial Responsibilities

Deputy Editor, Medical Care, 2002–present

Editorial Board, American Journal of Managed Care, 1998–present

Advisory Panel, Expert Review of Pharmacoeconomics and Outcomes Research (a peer-reviewed published journal), 2001–present

Institutional Review Board

Cancer Research and Biostatistics (CRAB), Seattle, Washington (John Crowley, Director), 2001–2004

Research Papers in Refereed Journals

In Press

1. ---
2. ---

3. ---
4. ---

Submitted

5. ---
6. ---
7. ---
8. ---
9. ---
10. ---
11. ---

2005

12. Ramsey SD, Sullivan S. Evidence, Economics, and Emphysema: Medicare's Long Journey with Lung Volume Reduction Surgery. *Health Affairs* 2005;24(1):55-66.
13. Zeliadt SB, Etzioni RD, Penson DF, Thompson IM, Ramsey SD. Lifetime Implications and Cost-Effectiveness of Using Finasteride to Prevent Prostate Cancer. *American Journal of Medicine* 2005;118(8):850-857.
14. Oestreicher N, Ramsey SD, Linden HM, McCune JS, van't Veer LJ, Burke W, Veenstra DL. Gene Expression Profiling and Breast Cancer Care: What are the Potential Benefits and Policy Implications? *Genetics in Medicine*. *Genetics in Medicine* 2005;7(6):380-389.
15. Epplein M, Koon KP, Ramsey SD, Potter JD. Genetic Services for Familial Cancer Patients: A Follow-up Survey of National Cancer Institute Cancer Centers. *Journal of Clinical Oncology* 2005;23(21):4713-4718.

2004

16. Ramsey SD, Mandelson MT, Etzioni R, Harrison R, Smith R, Taplin S. Can administrative data identify incident cases of colorectal cancer? A comparison of two health plans. *Health Services and Outcomes Research Methodology* 2004;5:27-37.
17. Ramsey SD, Sullivan SD. Chronic Obstructive Pulmonary Disease: is there a case for early intervention? *American Journal of Medicine* 2004;117(Suppl 12A):3S-10S. Review.
18. Ramsey SD, Howlader N, Etzioni RD, Donato B. Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from surveillance, epidemiology and end results-Medicare. *J Clin Oncol* 2004;22(24):4971-4978.
19. Zeliadt SB, Potosky AL, Etzioni R, Ramsey SD, Penson DF. Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. *Urology* 2004;64:1171-1176.
20. Custer B, Johnson ES, Sullivan SD, Hazlet TK, Ramsey SD, Hirschler NV, Murphy EL, Busch MP. Quantifying losses to the donated blood supply due to donor deferral and miscollection. *Transfusion* 2004;44:1417-1426.
21. Andersen MR, Urban N, Ramsey S, Briss PA. Examining the cost-effectiveness of cancer screening promotion. *Cancer* 2004;101(Suppl 5):1229-1238.

22. Phillips KA, Veenstra DL, Ramsey SD, Van Bebber SL, Sakowski J. Genetic testing and pharmacogenomics: Issues for determining the impact to healthcare delivery and costs. *American Journal of Managed Care* 2004;10(7 Pt 1):425-432.
23. Linden HM, Ramsey SD, Anderson N. An Ounce of Prevention or a Pound of Cure? Investing to Improve Breast Cancer Outcomes for African American Women. (Editorial) *Journal of Clinical Oncology* 2004; 22(13):2517-2518.
24. McKenna R, Benditt JO, DeCamp, M, Deschamps C; Kaiser L, Lee SM, Mohsenifar Z, Piantadosi S, Ramsey SD, Reilly J, Utz J. Safety and Efficacy of Median Sternotomy versus VATS for Lung Volume Reduction Surgery. *Journal of Thoracic and Cardiovascular Surgery* 2004;127(5):1350-1360.
25. Umar A, Boland C, Terdiman JP, Syngal S, de la Chapelle A, Ruschhoff J, Fishel R, Lindor NM, Burgart LJ, Hamelin R, Hamilton SR, Hiatt RA, Jass JR, Lindblom A, Lynch HT, Peltomaki P, Ramsey SD, Rodriguez-Bigas MA, Vasen H, Hawk E, Barrett J, Freedman AN, Srivastava S. Revised Bethesda guidelines for hereditary non-polyposis colorectal cancer and microsatellite instability. *Journal of the National Cancer Institute* 2004;96:261-268.
26. Bermejo C, Kristal AR, Zeliadt SB, Ramsey S, Thompson IM. Localized prostate cancer: quality of life meets Whitmore's legacy. *Journal of the National Cancer Institute* 2004;96(18):1348-1349.
27. Kessler L, Ramsey SD, Tunis S, Sullivan SD. Clinical use of medical devices in the 'Bermuda Triangle'. *Health Aff (Millwood)*. 2004;23(1):200-7.

2003

28. Ramsey SD. Cost effectiveness of lung-volume–reduction surgery. *Chest Surgery Clinics of North America* 2003;13(4):727-738.
29. Zhou X-HA, Ramsey S. Assessing the equality of means of healthcare costs. *Expert Review of Pharmacoeconomics and Outcomes Research* 2003;3(5):561-567.
30. Ramsey SD, Mandelson MT, Berry KM, Etzioni RD, Harrison R. Cancer-attributable costs of diagnosis and care for persons with screen-detected versus symptom-detected colorectal cancer. *Gastroenterology* 2003;125(6):1645-1650.
31. Ramsey SD, Burke W, Clarke L. An economic viewpoint on alternative strategies for identifying persons with hereditary nonpolyposis colorectal cancer. *Genetics in Medicine* 2003;5(5):353-363.
32. Ramsey SD, Berry KM, Etzioni, RD, Kaplan RM, Sullivan SD, Wood DE. Cost effectiveness of lung-volume-reduction surgery for patients with severe emphysema. *New England Journal of Medicine* 2003 May 22;348(21):2092-2102.
33. Etzioni R, Urban N, Ramsey SD, McIntosh M, Schwartz S, Reid B, Radich J, Anderson G, Hartwell L. The case for early detection. *Nature Reviews Cancer* 2003;3:243-252.
34. Ramsey SD, Wilson S, Spencer A, Geidzinska A, Newcomb P. Attitudes towards genetic screening for predisposition to colon cancer among cancer patients, their relatives and members of the community. Results of focus group interviews. *Community Genetics* 2003;6(1):29-36.
35. Ramsey SD, Sullivan SD. The burden of illness and economic evaluation for COPD. *European Respiratory Journal Supplement* 2003 Jun;41:29s-35s.

2002

36. Belza B, Topolski T, Kinne S, Patrick DL, Ramsey SD. Does adherence make a difference? Results from a community-based aquatic exercise program. *Nursing Research* 2002 Sep-Oct;51(5):285-291.
37. Ramsey SD, Kessler LG. Does economics matter when treating advanced non-small cell lung cancer? *Oncologist* 2002;7(3):179-180.
38. Nallamotheu BK, Saint S, Eagle KA, Langa KM, Fendrick AM, Hogikyan RV, Kelley K, Ramsey SD. Coronary artery bypass grafting in octogenarians: clinical and economic outcomes at community-based healthcare facilities. *American Journal of Managed Care* 2002 Aug;8(8):749-755.
39. Neil N, Ramsey SD, Cohen DJ, Every NR, Weaver DW; OPUS-I Investigators. Resource utilization, cost and health status impacts of coronary stent vs. "optimal" percutaneous coronary angioplasty: results from the OPUS-I trial. *Journal of Interventional Cardiology* 2002 Aug;15(4):249-255.
40. Etzioni R, Riley GF, Ramsey SD, Brown M. Measuring costs: administrative claims data, clinical trials, and beyond. *Medical Care* 2002 Jun;40(6 Suppl):III63-III72.
41. Ramsey SD. What is cancer outcomes research? A diversity of perspectives for an emerging field. *Medical Care*. 2002 Jun;40(6 Suppl):III1-III2.
42. Kessler L, Ramsey SD. The outcomes of the cancer outcomes research symposium: a commentary. *Medical Care*. 2002 Jun;40(6 Suppl):III104-III108.
43. Veenstra DL, Ramsey SD, Sullivan SD. A guideline for the use of pharmacoeconomic models of diabetes treatment in the US managed-care environment. *Pharmacoeconomics*. 2002;20 Suppl 1:21-30.
44. Ramsey SD, Berry K, Moinpour C, Giedzinska A, Andersen MR. Quality of life in long term survivors of colorectal cancer. *American Journal of Gastroenterology* 2002 May;97(5):1228-1234.
45. Goldberg HI, Neighbor WE, Hirsch IB, Cheadle AD, Ramsey SD, Gore E. Evidence-based management: using serial firm trials to improve diabetes care quality. *Joint Commission Journal on Quality Improvement* 2002 Apr;28(4):155-166.
46. Ramsey SD. Economic analyses and clinical practice guidelines: why not a match made in heaven? *Journal of General Internal Medicine* 2002 Mar;17(3):235-237.
47. Ramsey SD, Berry K, Etzioni R. Lifetime cancer-attributable cost of care for long term survivors of colorectal cancer. *American Journal of Gastroenterology* 2002 Feb;97(2):440-445.
48. Ramsey SD, Moinpour CM, Lovato LC, Crowley JJ, Grevstad P, Presant CA, Rivkin SE, Kelly K, Gandara DR. Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer. *Journal of the National Cancer Institute* 2002 Feb 20;94(4):291-297.
49. Hirsch I, Goldberg H, Ellsworth A, Evans T, Herter C, Ramsey S, Mullen M, Neighbor W, Cheadle A. A multifaceted intervention in support of diabetes treatment guidelines: a cont trial. *Diabetes Research and Clinical Practice* 2002 Oct;58(1):27.
50. Ramsey S, Summers KH, Leong SA, Birnbaum HG, Kemner JE, Greenberg P. Productivity and medical costs of diabetes in a large employer population. *Diabetes Care* 2002 Jan;25(1):23-29.

2001

51. Marciante KD, Ramsey SD. Short-term costs versus long-term gains: the trade-off for glitazone therapy. *Preventive Medicine in Managed Care* 2001;2(3 Suppl):S51-S63.
52. Nallamothu BK, Saint S, Ramsey SD, Hofer TP, Vijan S, Eagle KA. The role of hospital volume in coronary artery bypass grafting: is more always better? *Journal of the American College of Cardiology* 2001;38(7):1923-1930.
53. Yueh B, Souza P, McDowell J, Sarubbi M, Loovis C, Hedrick S, Ramsey S, Deyo R. Randomized trial of amplification strategies. *Archives of Otolaryngology—Head and Neck Surgery* 2001;127:1197-1204.
54. Lee TA, Sullivan SD, Veenstra DL, Ramsey SD, Stefer PJK, Malinverni R, Pleil AM, Williamson T. Economic evaluation of systemic treatments of cytomegalovirus retinitis in patients with AIDS. *Pharmacoeconomics* 2001;19(5 Pt 2):535-550.
55. Etzioni R, Ramsey SD, Berry K, Brown M. The impact of including future medical care costs when estimating the costs attributable to a disease: a colorectal cancer case study. *Health Economics* 2001 Apr;10(3):245-256.
56. Ramsey SD, Sullivan SD, Kaplan RM, Wood DE, Chiang YP, Wagner JL. Economic analysis of lung volume reduction surgery as part of the National Emphysema Treatment Trial. NETT Research Group. *Annals of Thoracic Surgery* 2001 Mar;71(3):995-1002.
57. McIntosh M, Ramsey SD, Berry K, Urban N. Parameter solicitation for planning cost effectiveness studies with dichotomous outcomes. *Health Economics* 2001;10:53-66.
58. Ramsey SD, McIntosh M, Sullivan SD. Design issues for conducting cost-effectiveness analysis alongside clinical trials. *Annual Review of Public Health* 2001;22:129-141.
59. Wagner EH, Sandhu N, Newton K, McCulloch DK, Ramsey SD, Grothaus LC. The effect of improved glycemic control on health care costs and utilization. *Journal of the American Medical Association* 2001;285:182-189.
60. Pauwels RA, Buist S, Calverley PMA, Jenkins CR, Hurd SS, GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of Chronic Obstructive Pulmonary Disease: NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop Summary. *American Journal of Respiratory and Critical Care Medicine* 2001;163:1256-1276.
61. Kelly K, Crowley J, Bunn PA Jr., Presane CA, Grevstad PK, Moinpour CM, Ramsey SD, Wozniak AJ, Weiss GR, Moore DF, Israel VK, Livingston RB, Gandara DR. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. *Journal of Clinical Oncology* 2001;19(13):3210-3218.
62. Chaiyakunapruk N, Boudreau D, Ramsey SD. Pharmaco-economic impact of HMG-CoA reductase inhibitors in type 2 diabetes. *Journal of Cardiovascular Risk* 2001;8(3):127-132.
63. Nallamothu BK, Saint S, Saha S, Fendrick AM, Kelly K, Ramsey SD. Coronary artery bypass grafting in Native Americans: a higher risk for death than other ethnic groups? *Journal of General Internal Medicine* 2001 Aug;16(8):554-559.

64. Ramsey SD, Cheadle AD, Neighbor WE, Gore E, Temple P, Staiger T, Goldberg HI. Relative impact of patient and clinic factors on compliance with primary care preventive services: an exploratory study. *Medical Care* 2001 Sep;39(9):979-989.
65. Ramsey SD, Spencer AC, Topolski TD, Belza BL, Patrick DL. Use of alternative therapies by older adults with osteoarthritis. *Arthritis and Rheumatism* 2001 Jun;45(3)222-227.
66. Patrick DL, Ramsey SD, Spencer A, Kinne S, Belza B, Topolski TD. Economic evaluation of aquatic exercise for persons with osteoarthritis. *Medical Care* 2001 May;39(5):413-424.
67. Ramsey SD, Clarke L, Etzioni R, Higashi M, Berry K, Urban N. Cost-effectiveness of microsatellite instability screening as a method for detecting hereditary nonpolyposis colorectal cancer. *Annals of Internal Medicine* 2001;135(8 Pt 1):577-588.

2000

68. Blough DK, Ramsey SD. Using generalized linear models to assess medical care costs. *Health Services and Outcomes Research Methodology* 2000;1:185-202.
69. Goldberg HI, Neighbor WE, Cheadle AD, Ramsey SD, Diehr P, Gore E. A controlled time-series trial of clinical reminders: using computerized firm systems to make quality-improvement research a routine part of mainstream practice. *Health Services Research* 2000;34:1519-1534.
70. Ramsey SD. Suboptimal medical therapy in Chronic Obstructive Lung Disease: exploring the causes and consequences. *Chest* 2000;117(2 Suppl):33S-37S.
71. Sullivan SD, Ramsey SD, Lee TA. The economic burden of COPD. *Chest* 2000 Feb;117(2 Suppl):5S-9S.
72. Ramsey SD, McIntosh M, Etzioni R, Urban N. Simulation modeling of outcomes and cost effectiveness. *Hematology/Oncology Clinics of North America* 2000;14:925-938.
73. Ramsey SD, Freedman AN, Berry K, Anderson MR, Urban N. Prevalence of pedigrees suggestive of hereditary nonpolyposis colorectal cancer among a community sample of women eligible for screening mammography. *Community Genetics* 2000;2:173-178.
74. Ramsey SD, Saint S, Sullivan SD, Dey L, Kelley K, Bowdle A. Clinical and economic effects of pulmonary artery catheterization in non-emergent coronary artery bypass graft surgery. *Journal of Cardiothoracic and Vascular Anesthesia* 2000;14:113-118.
75. Ramsey SD, Andersen MR, Etzioni R, Moinpour C, Peacock S, Potosky A, Urban N. Quality of life in survivors of colorectal carcinoma. *Cancer* 2000;88:1294-1303.
76. Maynard C, Ramsey SD, Wickizer T, Conrad DA. Healthcare charges and use in commercially insured children enrolled in managed care health plans in Washington State. *Maternal and Child Health Journal* 2000;4:29-38.

1999

77. Ramsey SD, Sullivan SD. Weighing the economic evidence: guidelines for critical assessment of cost-effectiveness analyses. *Journal of the American Board of Family Practice* 1999;12:477-485.

78. Ramsey SD. Evaluating evidence from a decision analysis. *Journal of the American Board of Family Practice* 1999 Sep-Oct;12(5):395-402.
79. Ramsey SD, Newton K, Blough D, McCulloch DK, Sandhu N, Wagner EH. Patient-level estimates of the cost of complications in diabetes in a managed care population. *Pharmacoeconomics* 1999;16:285-295.
80. Sommers S, Ramsey SD. A review of quality of life evaluations in men with prostate cancer. *Pharmacoeconomics* 1999 Aug;16(2):127-140.
81. Ramsey SD, Sullivan SD, Neil N, Perfetto E. An economic evaluation of the JNC hypertension guidelines using data from a randomized controlled trial. Joint National Committee. *Journal of the American Board of Family Practice* 1999 Mar-Apr;12(2):105-114.
82. Etzioni RD, Feuer EJ, Hu C, Lin D, Sullivan SD, Ramsey SD. On the use of survival analysis techniques to estimate medical care costs. *Journal of Health Economics* 1999;18(3):365-80.
83. Arnold RG, Kotsanos JG, Motheral B, Ramsey S, Crown W, Murray M. Methodological issues in conducting pharmacoeconomic evaluations-retrospective and claims database studies. *Journal of the International Society of Pharmaceutical Outcomes Research* 1999;2:82-87.
84. Newton KM, Wagner EH, Ramsey SD, McCulloch D, Evans R, Sandhu N, Davis C. The use of automated data to identify complications and comorbidities of diabetes: a validation study. *Journal of Clinical Epidemiology* 1999 Mar;52(3):199-207.
85. Blackmore CC, Ramsey SD, Frederick AM, Deyo RA. Cervical spine screening with computed tomography in trauma patients: a cost-effectiveness analysis. *Radiology* 1999;212(1):117-125.
86. Pauly MV, Ramsey SD. Would you like suspenders to go with that belt? An analysis of optimal combinations of cost sharing and managed care. *Journal of Health Economics* 1999;18:443-458.
87. Ramsey SD, Newton K, Blough D, McCulloch DK, Sandhu N, Reiber GE, Wagner EH. Incidence, outcomes, and cost of foot ulcers in patients with diabetes. *Diabetes Care* 1999;32:382-387.

1998

88. Spencer AC, Kinne S, Belza B, Ramsey SD, Patrick DL. Recruiting adults with osteoarthritis into an aquatics exercise class: strategies for a statewide intervention. *Arthritis Care and Research* 1998;11:455-462.
89. Huizenga H, Ramsey SD, Albert RA. Estimated growth of lung volume reduction surgery among medicare enrollees: 1994–1997. *Chest* 1998;114:1583-1587.
90. Ramsey SD, Luce BR. Technology assessment of medical devices. *American Journal of Managed Care* 1998;4:SP113-SP114.
91. Ramsey SD, Luce BR, Deyo R, Franklin G. The limited state of technology assessment for medical devices: facing the issues. *American Journal of Managed Care* 1998;4:SP188-SP199.
92. Zierler BK, Marcus-Smith MS, Cheadle A, Conrad DA, Kirz HL, Madden C, Noren J, Perrin EB, Ramsey SD, Ross A. The effect of compensation method on primary care physician behavior: evidence from interviews with Washington State physicians and medical leaders. *American Journal of Managed Care* 1998;4:209-220.

93. Conrad DA, Maynard C, Cheadle A, Ramsey S, Marcus-Smith M, Kirz H, Madden CA, Martin D, Perrin EB, Wickizer T, Zierler B, Ross A, Noren J, Liang S-Y. Primary care physician compensation method in medical groups: does it influence the use and cost of health services for enrollees in managed care organizations? *Journal of the American Medical Association* 1998;279:853-858.

1997

94. Ramsey SD, Pauly MV. Structural incentives and adoption of medical technologies in HMO and fee-for-service insurance plans. *Inquiry* 1997;34:228-236.
95. Ramsey SD, Etzioni R, Troxel A, Urban N. Optimizing sampling strategies for estimating quality-adjusted life years. *Medical Decision Making* 1997;17:431-438.
96. Ramsey SD, Sullivan SD, Psaty BM, Patrick DL. Willingness to pay for antihypertensive care: evidence from a staff model HMO. *Social Science and Medicine* 1997;44:1911-1917.
97. Ramsey SD, Hillman AH, Pauly MV. The effects of health insurance on access to new medical technologies. *International Journal of Technology Assessment in Health Care* 1997;13:357-367.

1996 and earlier

98. Conrad DA, Noren J, Marcus-Smith M, Ramsey SD, Wickizer T, Perrin E, Ross A. Physician compensation models in medical group practice. *Journal of Ambulatory Care Management* 1996;19:18-27.
99. Ramsey SD, Bavendam T, Wagner T. Estimated costs of treating urinary incontinence using the AHCPR guidelines. *American Journal of Managed Care* 1996;2:147-154.
100. Ramsey SD, Patrick DL, Albert RA, Larson EB, Wood DE, Raghu G. The cost-effectiveness of lung-transplantation: a pilot study. University of Washington Medical Center Lung Transplant Study Group. *Chest* 1995;108:1594-1601.
101. Ramsey SD, Patrick DL, Lewis S, Albert RK, Raghu G. Improvement in quality of life after lung transplantation: a preliminary study. *Journal of Heart and Lung Transplantation* 1995;14(5):870-877.
102. Ramsey SD, Rosenstock L. A proposal to reimburse occupational medicine disease and injury claims through third party health insurance. *American Journal of Industrial Medicine* 1994;26:147-154.
103. Ramsey SD, Hillman AL, Pauly MV, Kimberly JR, Schwartz JS. How important is the scientific literature in guiding clinical decisions? The case of magnetic resonance imaging. *International Journal of Technology Assessment in Health Care* 1992;9:253-262.
104. Ramsey SD, Nettleman, MD. The cost-effectiveness of prophylactic AZT following needle stick injury in health care workers. *Medical Decision Making* 1992;12:142-148.
105. Bloom BB, Fendrick AM, Ramsey SD. Changes in peptic ulcer and gastritis/duodenitis in Great Britain, 1970–1985. *Journal of Clinical Gastroenterology* 1990;12:100-108.

Editorials and Letters to the Editor

1. Ramsey SD. Screening for the Lynch syndrome. *New England Journal of Medicine* 2005 Aug 4; 353(5):524-525.

2. Ramsey SD. Aspirin, clopidogrel, or both for secondary prevention of coronary disease. *New England Journal of Medicine* 2003 Feb 6; 348(6):560-563; author reply 560-563.
3. Ramsey SD. Incorporating economic analysis into clinical practice guidelines: a guide for users. *ACP Journal Club* 2002 Nov-Dec;137(3):A11-A13.
4. Ramsey SD. Response regarding: Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer. *Journal of the National Cancer Institute* 2002;94(15):1172.
5. Jarvik JG, Ramsey S. Radiographic screening for orbital foreign bodies prior to MR imaging: is it worth it? *American Journal of Neuroradiology* 2000 Feb;21(2):245-247.
6. Ramsey SD. Methods for reviewing economic evaluations of community preventive services: a cart without a horse? *American Journal of Preventive Medicine* 2000 Jan;18(1 Suppl):15-17.
7. Ramsey SD, Larson EB. Response to Hosenpud et al. Effects of diagnosis on survival benefit of lung transplantation for end-stage lung disease. *Lancet* 1998;351:1285.
8. Ramsey SD, Patrick DL, Albert RA, Larson EB, Wood DE, Raghu G. Response to letter concerning "The cost-effectiveness of lung-transplantation: a pilot study." *Chest* 1995;108:1594-1601.
9. Ramsey SD. Managed care compels pharmaceutical industry to evaluate economic effectiveness of new products. *Oncology News International* 1995;4(14).

Textbooks

1. Evidence-Based Clinical Practice: Concepts and Approaches. Geyman J, Deyo R, Ramsey SD, editors. Butterworth Heinemann Publishers, Woburn, Massachusetts, 1999.

Book Chapters

1. Ramsey SD. Economic analyses alongside cancer clinical trials. Chapter 17 in *Handbook of Statistics in Clinical Oncology*, Taylor and Francis Group, LLC., Boca Raton, FL. *In press*.
2. Pinsky LE, Atkins D, Ramsey S, Burke W. Developing guidelines for the clinical use of genetic tests: a U.S. perspective. Chapter 16 in *Human Genome Epidemiology: A Scientific Foundation for Using Genetic Information to Improve Health and Prevent Disease*, Khoury MJ, Little J, Burke W, editors. Oxford University Press, New York, 2004.
3. Ramsey SR, Sullivan SD. Economic burden of acute exacerbations of chronic obstructive pulmonary disease. Chapter 4 in *Acute Exacerbations of Chronic Obstructive Pulmonary Disease*, Siafakas NM, Anthonisen NR, Georgopoulos D, editors. Marcel Dekker, Inc., New York, 2004.
4. Ramsey SR, Lee T, Sullivan SD. Financial aspects of emphysema and emphysema surgery. Chapter 19 in *Lung Volume Reduction Surgery for Emphysema*, Fessler HE, Reilly JJ Jr., Sugarbaker DJ, editors. Marcel Dekker, Inc., New York, 2003.
5. Sullivan SD, Ramsey SR, Wiess K. Economics in asthma. Chapter 52 in *Manual of Asthma Management*, 2nd

ed., O'Byrne PM and Thomson NC, editors. WB Saunders, New York, 2000.

6. Ramsey SD, Sullivan SD. Economic evaluation of asthma treatments. In *Socioeconomic Factors in Asthma*, Weiss K and Sullivan SD, editors. Marcel Dekker Monograph Series, 1999.
7. Ramsey SD, Raghu G. Economics of transplantation. Chapter 59 in *Primer on Lung Transplantation*, Norman DJ and Suki WN, editors. American Society of Transplant Physicians Publications, Thorofare, New Jersey, 1998.
8. Ramsey, SD. Quality of life in an economic context. In *Encounters in Glaucoma Research 3: How to Ascertain Progression and Outcome*, Anderson DR and Drance SM, editors. Kugler Publications, Amsterdam, 1996.
9. Kimberly JR, Renshaw LR, Ramsey SD, Hillman AL, Schwartz JS. Medical technology meets DRG's: acquiring magnetic resonance imaging under prospective payment. Chapter 13 of *Health Care, Technology, and the Competitive Environment*, Brehm HP and Mullner RM, editors. Praeger Publishing, New York, 1990.

Special Reports

1. Guidelines for economic evaluation of cancer clinical trials. NCI Monograph, Journal of the National Cancer Institute, 1998.
2. Costs and effectiveness of prostate cancer screening in elderly men, OTA-BP-H-145, U.S. Congress, Office of Technology Assessment (Washington D.C.: U.S. Government Printing Office, May 1995).

Research Funding

Submitted

Currently Funded Research

Principal Investigator, "The Cost-Effectiveness of Lung Volume Reduction Surgery." Sponsor: National Heart, Lung, and Blood Institute. Project dates: 5/1/1998–12/31/2005. Annual direct costs: \$1,000,000.

Principal Investigator, "A Genetic Screening Policy Model for Colorectal Cancer." Sponsor: ---. Project dates: 9/27/2004 – 8/31/2007. Annual direct costs: \$---.

Principal Investigator; "Localized Prostate Cancer: Decision Making and Outcomes." Sponsor: Centers for Disease Control (sub-award from ----, --- principal investigator). Project dates: 9/30/2004 – 9/29/2007. Total direct costs: \$392,000.

Principal Investigator, "SEER Special Studies: Special Study #04-5 "Treatment Choice and Quality of Life for Men with Localized Prostate Cancer." Sponsor: National Cancer Institute. Project dates: 9/30/2004 – 9/29/2006. Total direct costs: \$268,612.

Co-Investigator, and Principal Investigator for Special Project, “CanCORS: Lung/Colon Cancer Outcomes.” Sponsor: ---. Project dates: 9/18/2001–8/31/2007. Annual direct costs: \$---.

Principal Investigator, “Treatment Patterns and Direct Medical Costs for Persons Age 65 and Higher with Advanced Bladder Cancer.” Sponsor: ---. Project Dates: 2/1/05 – 1/31/06. Annual Direct Costs: \$---

Principal Investigator, “Patterns of Health Care Utilization and Medical Costs for Persons with Non-Small Cell Lung Cancer.” Sponsor: ---. Project Dates: 3/1/05 – 2/28/06. Annual Direct Costs: \$---

Co-Investigator, “Genomic Health Care and the Medically Underserved.” Sponsor: NIH/NHGRI (sub-award from ---). Project dates: 7/1/2004 – 6/30/2009. Total direct costs: \$215,000.

Co-Principal Investigator, “Biobehavioral Cancer Prevention and Control Training Program.” Sponsor: National Cancer Institute R25 Training Grant (sub-award from ---). Project dates: 7/11/2001–6/30/2006. Annual direct costs: \$240,579.

Co-Principal Investigator, “Project 4: Linking the SEER Cancer Registry with Indian Health Service Records.” Sponsor: NIH/NCI (sub-award from ---). Project dates: 9/29/2004 – 9/28/2007. Initial direct costs: \$60,717.

Co-Investigator, “Modeling Ovarian Cancer Screening for CEA.” Sponsor: NIH/NCI (Nicole Urban, PI). Project dates: 7/01/2002 – 6/30/2006. Annual direct costs: \$166,250.

Co-Principal Investigator, “Template for and Application of Clinical and Economic Evaluation of Clinical Laboratory Testing Technologies.” Sponsor: ---. Project Dates: 12/1/04 – 12/31/05. Annual direct costs: \$---

Co-Principal Investigator, “A Roadmap for Early Detection.” Sponsor: ---. Project Dates: 7/1/04 – 9/30/05. Annual direct costs: \$---

Co-Investigator, “Cervical Cancer Control in Vietnamese Women.” Sponsor: NIH/NCI. Project Dates: 8/03/05 – 5/31/08. Annual direct costs: \$350,000.

Co-Investigator, “Regional Native American Community Networks Program.” Sponsor: NIH/NCI. Project Dates: 4/01/05 – 3/31/10. Annual direct costs: \$90,000.

Previously Funded Research

Co-Investigator, “Center for the Evaluation of Biomarkers for the Early Detection of Breast Cancer.” Sponsor: DOD/CDMRP (Nicole Urban, PI). 2002 – 2005 (Project continues to 2006). Annual direct costs: \$1,114,579.

Co-Investigator, “Delivering Genetic Services.” Sponsor: ---. 2004 - 2005. Annual direct costs: \$---

Co-Investigator, “Pacific Ovarian Cancer Research Consortium: SPORE in Ovarian Cancer.” Sponsor: NIH/NCI (Nicole Urban, PI). 2004 – 2005 (Project continues to 2009). Annual direct costs: \$1,925,970.

Principal Investigator, SEER Special Studies: Special Study #01-13 “Lung Cancer Screening with Spiral Computed Tomography: A Surveillance Project.” Sponsor: National Cancer Institute. 2002 – 2005. Total direct costs: \$158,349.

Principal Investigator, “Effect of Treatment on Health-Related Quality of Life Among Prostate Cancer Survivors.” Sponsor: Centers for Disease Control (Subaward from ---). 2003 – 2004. Total direct costs: \$---.

Principal Investigator, “Burden of Illness and Direct Costs of Medical Care of Colon Cancer.” Sponsor: ---. 2000 – 2003. Total direct costs: \$---.

Principal Investigator, “SEER Special Study #19: Feasibility of Linking Health Systems Data to Cancer Registry Data.” Sponsor: National Cancer Institute. 2000 – 2003. Annual direct costs: \$141,027.

Principal Investigator, “Correlation of Endoscopy Frequency with Survival for Individuals Diagnosed with Local and Regional Colorectal Cancer.” Sponsor: National Cancer Institute. 2001 – 2003. Total direct costs: \$25,814.

Principal Investigator, “Health Care Utilization and Direct Medical Costs for Persons with Non-Small Cell Lung Cancer.” 2002 – 2004. Sponsor: ---. Annual direct costs: \$---.

Co-Investigator, “Evaluating the Use of Genetic Information: A Model Process.” Sponsor: National Institute for Human Genome Research (Wylie Burke, PI). 2001 – 2004. Annual direct costs: \$370,000.

Principal Investigator, “The Cost-Effectiveness of Genetic Screening for Hereditary Nonpolyposis Colorectal Cancer.” Sponsor: National Cancer Institute (Howard Temin Award: 5-year career development award). 1998 - 2003. Annual direct costs: \$137,113.

Principal Investigator, “Interdisciplinary Model for Studying Lung Cancer.” Sponsor: --- dates: February–July 2001. Funding: \$---.

Co-principal investigator, HBSI Fellowship Training Grants Program, Sponsor: ---. Start date: February 1999. Funding: \$---.

Principal investigator, “Risk Adjusting Population-Based Performance Measures.” Sponsor: ---. Start date: February 1998. Funding: \$---.

Principal investigator: “Cost and Quality of Life of Long-Term Survivors of Colon Cancer.” Sponsor: National Cancer Institute. Start date: October 1997. Funding: \$264,346.

Co-Investigator, “Staged Diabetes Management Trial.” Principal Investigator: ---. Sponsor: ---, 1997– 1999. Funding: \$---

Principal investigator, “Costs and Quality of Life in Survivors of Colon Cancer.” Sponsor: National Cancer Institute, Division of Cancer Prevention and Control, 1997–1998. Funding level: \$165,000

Co-investigator, “The Cost-Effectiveness of a Community-Based Arthritis Foundation-Sponsored Exercise Intervention for Patients with Osteoarthritis.” Principal investigator: Donald Patrick. Sponsors: Centers for Disease Control, ---, 1996–1998.

Co-investigator, “Clinical Outcomes Measure Amended HEDIS Demonstration Project.” Principal investigator: ---. Sponsor: ---, 1996–1997.

Co-investigator, “The Effects of Physician Compensation Method on Health Services Utilization and Cost in Managed Care Organizations.” Principal investigator: ---. Sponsor: ---, 1996–1997.

Co-investigator, “Costs of Complications Related to Diabetes.” Principal investigator, ---, 1996–1997.
Funding: \$---.

Consultant, “The Effects of Physician Compensation Method on Health Services Utilization and Cost in Managed Care Organizations (Phase II).” Principal investigator: ---. Sponsor: ---, September 1997.

Co-principal investigator, “Quality of Life Related to Colon Cancer and Colon Cancer Screening.” Principal Investigator, Nicole Urban. Sponsor: National Cancer Institute, September 1996. Funding: \$135,289.

Principal investigator, “Task Force on Technology Assessment of Medical Devices.” Sponsor: Department of Labor and Industries, State of Washington, June 1996. Funding: \$117,449.

Teaching

University of Washington Graduate Courses

Seminar in Biobehavioral Interventions, Communications, and Cancer Outcomes I, Health Services 574 (Director): spring 2002 and fall 2003.

Pharmacoeconomics, Genetics, and Healthcare, Public Health Genetics 537 (Co-Director), spring 2002, 2003, 2004.

Pharmaceutical Outcomes Seminar, Pharmacy 547 (Co-Director), spring 2000, 2001, 2002.

Economic and Policy Issues For Genetic Technologies And Services, Public Health Genetics 541, School of Public Health, Fall Quarter 2003

Seminar in Biobehavioral and Outcomes Research, Health Services 590, School of Public Health, Winter Quarter, 2004

Seminar in Cancer Prevention and Control, Health Services 575, School of Public Health, Winter Quarter, 2005

Mentorship of Trainees (Current)

Special Fred Hutchinson Responsibilities

Director, Outcomes Research Affinity Group, 2000–present

Member, Solid Tumor Scientific Review Committee, 2002–present

Member, Pacific Health Summit Steering Committee, 2004–present

Member, SCCA/FHCRC Prevention Clinic Planning Committee, 2004–present

Manuscript Review Duties

Annals of Internal Medicine
Cancer
Chest
Health Economics
HSR: Health Services Research
Journal of Clinical Oncology

Journal of the National Cancer Institute
Medical Decision Making
New England Journal of Medicine
Pharmacoeconomics
Quality of Life Research